Remus Vezan
Direktor/Vorstandsmitglied bei Carina Biotech Pty Ltd.
Aktive Positionen von Remus Vezan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Direktor/Vorstandsmitglied | 05.06.2023 | - |
Independent Dir/Board Member | 05.06.2023 | - |
Karriereverlauf von Remus Vezan
Ausbildung von Remus Vezan
University of Medicine | Doctorate Degree |
Statistik
International
Australien | 2 |
Niederlande | 2 |
Operativ
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |
- Börse
- Insiders
- Remus Vezan
- Erfahrung